Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Shields

Showing results (321-330 of 413) with videos related to

Pageof 42
Sort By:
Cell Metabolism|June 7, 2011
mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle massSteven D Kunkel, Manish Suneja, Scott M Ebert, et al.
Antimicrobial Agents and Chemotherapy|June 1, 2017
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae BacteremiaRyan K Shields, M Hong Nguyen, Liang Chen, et al.
The Journal of Antimicrobial Chemotherapy|May 26, 2019
Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258Alina Iovleva, Roberta T Mettus, Christi L McElheny, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2018
Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organismsE Wenzler, M Lee, T J Wu, et al.
Antimicrobial Agents and Chemotherapy|June 2, 2025
Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapyGriffin Reed, Adrian Valadez, Brandon J Smith, et al.
PHAGE (New Rochelle, N.Y.)|September 23, 2022
Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical IsolatesAmanda G Finney, Jalyne M Perry, Daniel R Evans, et al.
Infection and Immunity|March 14, 2022
Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant Staphylococcus aureus BacteremiaMitra M Elgrail, Edwin Chen, Marla G Shaffer, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 3, 2010
Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection?M-L Luong, B Sareyyupoglu, M H Nguyen, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Differential virulence potential of different clades of multidrug-resistant <i>Klebsiella pneumoniae</i> ST258Nathalie Chen, Brooke P Dresden, Margaret Cassady, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2019
Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i>William R Wilson, Ellen G Kline, Chelsea E Jones, et al.
Pageof 42

Showing results (321-330 of 413) with videos related to

Sort By:
Pageof 42
Cell Metabolism|June 7, 2011
mRNA expression signatures of human skeletal muscle atrophy identify a natural compound that increases muscle massSteven D Kunkel, Manish Suneja, Scott M Ebert, et al.
Antimicrobial Agents and Chemotherapy|June 1, 2017
Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae BacteremiaRyan K Shields, M Hong Nguyen, Liang Chen, et al.
The Journal of Antimicrobial Chemotherapy|May 26, 2019
Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258Alina Iovleva, Roberta T Mettus, Christi L McElheny, et al.
The Journal of Antimicrobial Chemotherapy|December 12, 2018
Performance of ceftazidime/avibactam susceptibility testing methods against clinically relevant Gram-negative organismsE Wenzler, M Lee, T J Wu, et al.
Antimicrobial Agents and Chemotherapy|June 2, 2025
Population pharmacokinetics of meropenem-vaborbactam in acutely ill hospitalized patients with various degrees of renal dysfunction including continuous renal replacement therapyGriffin Reed, Adrian Valadez, Brandon J Smith, et al.
PHAGE (New Rochelle, N.Y.)|September 23, 2022
Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical IsolatesAmanda G Finney, Jalyne M Perry, Daniel R Evans, et al.
Infection and Immunity|March 14, 2022
Convergent Evolution of Antibiotic Tolerance in Patients with Persistent Methicillin-Resistant Staphylococcus aureus BacteremiaMitra M Elgrail, Edwin Chen, Marla G Shaffer, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|November 3, 2010
Lactobacillus probiotic use in cardiothoracic transplant recipients: a link to invasive Lactobacillus infection?M-L Luong, B Sareyyupoglu, M H Nguyen, et al.
Medrxiv : the Preprint Server for Health Sciences|April 10, 2026
Differential virulence potential of different clades of multidrug-resistant <i>Klebsiella pneumoniae</i> ST258Nathalie Chen, Brooke P Dresden, Margaret Cassady, et al.
Antimicrobial Agents and Chemotherapy|January 9, 2019
Effects of KPC Variant and Porin Genotype on the <i>In Vitro</i> Activity of Meropenem-Vaborbactam against Carbapenem-Resistant <i>Enterobacteriaceae</i>William R Wilson, Ellen G Kline, Chelsea E Jones, et al.
Pageof 42